http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jiri Panek (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Self-association of bee propolis: effects on pharmaceutical applications
Jiri Trousil,Martin Hruby,Jiri Panek,Jana Matějková,Jan Kucka,Petr Stepanek 한국약제학회 2014 Journal of Pharmaceutical Investigation Vol.44 No.1
Propolis is a resinous product collected byhoneybees from various plant sources; it is widely used intraditional medicine and has been reported to have a broadspectrum of pharmacological effects (i.e., antibacterial,antifungal, antiviral and anti-inflammatory effects). Themost commonly used propolis formulations are gargles, inwhich propolis tinctures are diluted with water. The dilutionprocess is accompanied by nanoprecipitation, and thepropolis droplets are dispersed in the prepared gargle. Inthe present study, we investigated the dependence of theproperties of propolis nanodispersions on the method ofpreparation. The particle size was found to be approximately150 nm and was observed to decrease withincreasing dilution as the zeta potential of the particlesbecame more negative, which stabilized the dispersion. The dispersion dissolved upon alkalization and reprecipitatedduring acidification. The addition of salt destabilizedthe dispersion. The uptake of propolis from the dispersionwas modeled using 1-octanol and was found to be rapidand only slightly dependent on the nanoparticle size. Propolis susceptibility tests showed that the most effectivedispersion of propolis was tenfold-diluted EEP (P-80-10and JP-80-10). The disc diffusion method was used toevaluate the antibacterial activity of chosen dispersions ofpropolis against Staphylococcus aureus, Escherichia coliand Candida albicans. Propolis samples with differentlocations of origin exhibited different effects against thestrain of C. albicans.
-
( Tomas Andrasina ),( Vlastimil Valek ),( Jiri Panek ),( Zdenek Kala ),( Igor Kiss ),( Stepan Tucek ),( Pavel Slampa ) 대한소화기기능성질환·운동학회 2010 Gut and Liver Vol.4 No.s1
Background/Aims: To prospectively evaluate our palliative management of unresectable cholangiocarcinoma (CC) treated with tailored multimodal oncological therapy. Methods: Between January 2005 and January 2010, 50 consecutive patients with unresectable CC and jaundice were palliated with percutaneous drainage. Forty-three patients underwent metallic- stent implantation followed by brachytherapy. Patients were divided into two arms: the intra-arterial chemotherapy arm (IA arm, n=17) consisted of patients treated with locoregional treatment (IA admission of Cisplatin and 5-fluorouracil, or chemoembolization with Lipiodol) and/or systemic chemotherapy, while the systemic chemotherapy arm (IV arm, n=23) included all the other patients, who were treated only with systemic chemotherapy. Results: In total, 78 metal self-expandable stents were placed. Hilar involvement with mass-forming and periductal infiltrating types of CC (84%) was predominant. The average number of percutaneous interventional procedures was 11.61 per patient (range, 4-35). The median overall survival from diagnosis of disease for all patients was 13.5 months (range, 11.0-18.8 months). The median overall survival times were 25.2 months (range, 15.2-31.3 months) and 11.5 months (range, 8.5-12.6 months) in the IA and IV arms, respectively (p<0.05). The 1-, 2-, and 3-year survival rates in the IA and IV arms were 88.2%, 52.9%, and 10.1% and 43.5%, 25.4, and 0%, respectively. There were no major complications (WHO III/IV) due to interventional procedures. Conclusions: We could reach acceptable prognosis in patients with unresectable CC using complex tailored oncological therapy. However, the main limitations of prolonging survival are performance status, patient compliance and the maintaining of biliary tract patency. (Gut Liver 2010;4(Suppl. 1):S82-88)
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
